Is NCT06190886 recruiting in Omaha, NE?

Yes, NCT06190886 is currently recruiting participants at its Omaha, NE location. This advanced cancer clinical trial is actively enrolling qualified participants.

How do I join the advanced cancer clinical trial in Omaha?

To join this clinical trial in Omaha, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Omaha clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Advanced Cancer Clinical Trial in Omaha, NE

About This Advanced Cancer Study in Omaha

The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912. To evaluate the preliminary anti-tumor activity of PTX-912. Participants will be treated with PTX-912 via iv infusion, every 2 weeks until progression of disease, unacceptable toxicity, or 12 months of total study therapy.

Sponsor: Proviva Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures.

Male and Female patients age ≥ 18 years on day of signing informed consent.

Willing to comply with all protocol-required visits, assessments, and procedures.

Patients with locally advanced or metastatic solid tumors who have had disease progression on all available standard of care or for whom no reasonable standard of care exists that would confer clinical benefit.

Recovery from all toxicities associated with prior therapy to acceptable baseline status (for laboratory toxicities, see limits for inclusion). NCI CTCAE v5.0 Grade 0 or 1, except for toxicities not considered a safety risk (e.g., alopecia or vitiligo).

Measurable disease per RECIST v1.1.

Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 with no deterioration during Screening.

Adequate bone marrow and organ function, defined by the following laboratory results obtained within 14 days before first dose of study drug.

Patients with recent major surgery must have adequately recovered with no ongoing complications from the surgery prior to receiving study treatment.

Willingness to adhere to the study treatment-specific contraception requirements.

Estimated life expectancy of 3 months (12 weeks) or greater as determined by Investigator.

Exclusion Criteria

Has a diagnosis of immunodeficiency.

Has an active infection requiring systemic therapy within 4 weeks prior to study treatment.

History of or known intolerance, significant hypersensitivity, or anaphylaxis to any components of PTX-912 or any of the excipients.

Unresolved toxicities from prior systemic therapy greater than NCI CTCAE grade 1 at time of first dose, except alopecia, vitiligo, and grade 2 neuropathy due to prior chemotherapy.

Experienced clinically significant immune-related toxicity from prior immunotherapy that in the opinion of the investigator would preclude protocol therapy or would make the patient inappropriate for the study.

Major surgery within 30 days prior to first dose of study drug (with the below exceptions), or anticipation of major surgery during study treatment.

Active autoimmune disease requiring systemic treatment within the past 3 months or have a documented history of clinically severe autoimmune disease that requires systemic steroids or immunosuppressive agents.

Uncontrolled diabetes mellitus or other uncontrolled immune-related endocrinopathies in the opinion of the investigator.

Primary central nervous system (CNS) disease or leptomeningeal disease.

Impaired cardiovascular function or clinically significant cardiovascular disease.

Abnormal pulmonary function within the previous 6 months, including history of pneumonitis, active pneumonitis, interstitial lung disease requiring the use of steroids, idiopathic pulmonary fibrosis, active pleural effusion, severe dyspnea at rest or requiring supplementary oxygen therapy.

History of allogenic, bone marrow, or solid organ transplants.

Received a live-virus vaccination ≤14 days prior to first dose of study drug (seasonal flu and other inactivated vaccines that do not contain live virus are permitted).

Clinically significant bleeding within 2 weeks prior to first dose of study drug dy.

Pregnant or breast-feeding women or expecting to conceive within the projected duration of the trial, starting with the screening visit through 3 months after the last dose of study drug.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Omaha?

Yes, this clinical trial (NCT06190886) has an active research site in Omaha, NE that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Cancer Treatment Options in Omaha, NE

If you're searching for advanced cancer treatment options in Omaha, NE, this clinical trial (NCT06190886) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Omaha research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced cancer clinical trials near you to find additional studies recruiting in your area.

Advanced Cancer Clinical Trial in Omaha, NE

Expert Care in Omaha

IRB Approved

No-Cost Care

Apply for This Omaha Location

Why Participate?

Simple Process